LifeMD, Inc. (NASDAQ:LFMD) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analyst consensus: LifeMD has an average recommendation of "Moderate Buy" from nine analysts (7 buys, 1 hold, 1 sell) with a 12‑month average price target of about $9.14.
• Recent results missed expectations: LifeMD reported EPS of −$0.04 vs. consensus −$0.01 and revenue of $46.87M vs. $48.57M, and analysts forecast ~−0.56 EPS for the fiscal year; the company also shows a negative ROE (−83.93%).
• Market and ownership snapshot: Shares trade near $3.47 with a market cap of about $166M, a 52‑week range of $2.56–$15.84, and institutional investors hold roughly 35.52% of the stock.

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $9.1429.

LFMD has been the subject of a number of recent analyst reports. Cantor Fitzgerald reissued an "overweight" rating on shares of LifeMD in a report on Tuesday, March 10th. Loop Capital set a $10.00 price objective on LifeMD in a report on Thursday, March 12th. Zacks Research upgraded LifeMD from a "strong sell" rating to a "hold" rating in a research report on Friday, December 19th. HC Wainwright upped their target price on LifeMD from $9.00 to $10.00 and gave the stock a "buy" rating in a research report on Wednesday, March 11th. Finally, Mizuho upgraded LifeMD from a "neutral" rating to an "outperform" rating and upped their target price for the stock from $6.00 to $8.00 in a research report on Monday, March 16th.

Institutional Trading of LifeMD

Hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC lifted its holdings in shares of LifeMD by 110.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company's stock valued at $64,000 after purchasing an additional 2,452 shares in the last quarter. Quarry LP acquired a new position in LifeMD during the third quarter worth $52,000. King Wealth Management Group acquired a new position in LifeMD during the third quarter worth $68,000. Legal & General Group Plc increased its position in LifeMD by 187.4% during the second quarter. Legal & General Group Plc now owns 10,144 shares of the company's stock worth $138,000 after buying an additional 6,614 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of LifeMD in the fourth quarter valued at about $36,000. Hedge funds and other institutional investors own 35.52% of the company's stock.

LifeMD Trading Up 2.1%

NASDAQ:LFMD opened at $3.47 on Friday. The firm has a market capitalization of $166.46 million, a PE ratio of 13.35 and a beta of 1.77. The stock has a 50 day moving average of $3.35 and a 200-day moving average of $4.21. LifeMD has a 52 week low of $2.56 and a 52 week high of $15.84.

LifeMD (NASDAQ:LFMD - Get Free Report) last posted its earnings results on Monday, March 9th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.03). LifeMD had a net margin of 6.58% and a negative return on equity of 83.93%. The company had revenue of $46.87 million for the quarter, compared to the consensus estimate of $48.57 million. As a group, analysts predict that LifeMD will post -0.56 EPS for the current fiscal year.

LifeMD Company Profile

LifeMD NASDAQ: LFMD is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company's core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD's service portfolio spans several specialty areas, including men's health, hormonal therapy, weight management and primary care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.